Study of Whole-Body MRI with Artificial Intelligence to Detect Pre-Cancerous Lesions in Children and Teens with Neurofibromatosis Type 1

What this Trial Is About

Researchers are evaluating a new approach using whole-body Magnetic Resonance Imaging MRI combined with artificial intelligence to study pre-malignant lesions in children aged 5 to 17 years with neurofibromatosis type 1. This pilot trial aims to assess how reliable the MRI scans are when repeated and to estimate how well changes detected by the AI in MRI images over 12 months predict the conditions progression. The study is conducted at Cedars-Sinai Medical Center and involves 15 pediatric patients. Participants will undergo whole-body MRI scans at three time points the start of the study baseline, one month later, and at approximately 12 months. The AI algorithm will analyze these scans to evaluate the agreement between the baseline and 1-month scans using T2 imaging, and to compare baseline scans to the 12-month scans using T1 and apparent diffusion coefficient imaging. This helps to understand the scan reliability and the predictive value of MRI changes over time. During the study, children will have MRI scans without sedation if possible, and their images will be carefully reviewed using advanced imaging techniques and AI analysis. Researchers will monitor scan consistency and changes over the year-long period. The primary measure is the agreement between baseline and 1-month scans, while secondary measures assess changes up to 12 months. Participation involves regular imaging visits and close monitoring until the study ends in May 2029.

Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence